Tenet Healthcare Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Tenet operates Hospital Operations and Ambulatory Care (USPI). Dollars below are U.S. dollars; financial amounts are in millions unless noted.
Financial and operating results
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Net operating revenues | $5,368 | $5,021 | Up 6.9% |
| Operating income | $3,285 | $603 | Includes $2,500 of net facility-sale and related gains, versus $13 |
| Net income attributable to Tenet common shareholders | $2,151 | $143 | Reported results substantially lifted by divestiture gains |
| Diluted EPS | $21.38 | $1.32 | Also substantially affected by divestiture gains |
| Adjusted EBITDA | $1,024 | $832 | Up 23.1%; margin 19.1% versus 16.6% |
| Cash from operating activities | $586 | $449 | Change affected by operating performance, working capital and timing items |
| Capital expenditures | $240 | $235 | Full-year 2024 estimate: approximately $800–$900 |
Revenue increased in both segments: Hospital Operations rose 6.2% to $4,373, and Ambulatory Care increased 9.9% to $995. Management cited payer mix, volume and acuity, negotiated commercial rate increases, $88 of additional Michigan Medicaid supplemental revenue, and ambulatory acquisitions. Same-hospital Hospital Operations revenue rose 8.8%; adjusted admissions increased 1.8%. Ambulatory consolidated cases increased 7.7%, partly reflecting acquired facilities.
Operating income and GAAP earnings are not representative of underlying quarter-on-quarter operating performance without considering the $2,500 in facility-sale and related gains. Adjusted EBITDA, a company-defined non-GAAP measure, was $1,024; the filing cautions it is not a liquidity measure and may not be comparable with similarly titled measures at other companies.
Cash, debt and liquidity
- Cash and equivalents were $2,481 at March 31, 2024, versus $1,228 at year-end 2023. Investing cash flow was $3,328, principally reflecting $4,030 of proceeds from facility and other asset sales; financing used $2,661.
- Long-term debt, including current maturities, was $12,879, down from $15,002 at December 31, 2023. Tenet redeemed $2,100 of 2026 first-lien notes with cash; the redemption generated an $8 early-extinguishment loss. Net debt using reported cash was approximately $10.4 billion.
- Management reported net debt to last-twelve-month Adjusted EBITDA of 2.79x. All current long-term debt is fixed-rate, apart from any future revolving-credit borrowings.
- No revolver borrowings were outstanding; the full $1,500 revolving facility was available. Tenet reported compliance with its credit and letter-of-credit facility covenants. It also had $110 of standby letters of credit under its separate LC facility.
- Accounts receivable rose to $3,148 from $2,914. Receivable days increased to 58.1 from 55.4 at year-end, above Tenet’s target of less than 55 days; the Change Healthcare cyberattack disrupted billing and collections.
Material changes and unusual items
- Tenet completed sales of three South Carolina hospitals, four hospitals in Orange and Los Angeles counties, and two hospitals in San Luis Obispo County, plus two South Carolina surgery centers. The hospital sales generated gains of $1,673, $529 and $278, respectively; the ASC sale generated a $23 gain.
- The divestitures affected the operating footprint: Tenet reported 52 hospitals at quarter-end, compared with 61 a year earlier. The filing attributes lower total surgeries in the reported continuing-operations comparison partly to the South Carolina hospital sale.
- USPI acquired controlling interests in 45 ambulatory surgery centers and opened one de novo ASC; it reported 380 consolidated facilities at quarter-end. Acquisition cash paid, net of cash acquired, was $449.
- Tenet repurchased 2.811 million shares for $278, averaging $98.86 per share. The repurchase program had $272 remaining and is scheduled to expire December 31, 2024.
- Tenet combined its former Hospital Operations and Conifer reporting segments into Hospital Operations during Q4 2023 and recast prior-period segment information.
Outlook, commentary and risks
- Tenet provided no company-wide earnings or Adjusted EBITDA guidance in the supplied filing. It estimated 2024 continuing-operations capital expenditures of approximately $800–$900.
- Management said existing cash, revolver availability and expected operating cash flow should meet current cash needs, while noting liquidity depends on collections, operating results, future financing conditions and other uses of cash. It continues to target debt reduction over time.
- Management cited persistent labor shortages, inflation and high medical-supply costs; recruitment and retention reduced contract-labor expense year over year, but labor costs remain elevated. California minimum-wage changes are expected to raise some costs.
- Key business risks include reimbursement and regulatory changes, state Medicaid budget pressure and potential payment delays, managed-care negotiations and payer concentration, patient volumes and shifts to outpatient care, and collection uncertainty. The top 10 managed-care payers generated 68% of managed-care patient service revenue.
- The Change Healthcare cyberattack impaired billing and collection activity, although Tenet said its own systems were not compromised and does not expect a permanent increase in receivable days. Medicaid eligibility redeterminations may increase uncompensated care.
- Tenet operates in a highly regulated and litigious industry. It says existing ordinary-course claims are not expected to materially affect business or financial condition, but adverse outcomes in legal or government matters could materially affect results or cash flows. The filing reports $1,060 of professional and general liability reserves and $316 maximum potential payments under certain physician guarantees, against a recorded liability of $246.
- CMS’s proposed FY2025 inpatient rule was estimated by Tenet to increase annual Medicare fee-for-service IPPS payments by about $29, subject to rule changes and other uncertainties. For finalized 2024 outpatient payment rules, Tenet estimated increases of about $23 for Hospital Operations and $16 for USPI. These are estimates, not company earnings guidance.
Important facts for investors to verify
- How much of reported earnings and cash available after the quarter’s sales is sustainable from continuing operations, excluding divestiture gains and related tax effects.
- Whether revenue growth, Adjusted EBITDA and margins persist after the hospital dispositions and as acquired USPI facilities are integrated.
- Whether receivable days return toward Tenet’s target after the Change Healthcare disruption, and whether cash collections and payer aging remain sound.
- The ongoing contribution and durability of Michigan Medicaid supplemental revenue, alongside potential state and federal reimbursement changes.
- Debt reduction, net leverage, share repurchases and acquisition spending relative to future operating cash flow and capital expenditure needs.
- Developments in legal matters, physician guarantees, liability reserves, labor costs and other contingencies that could affect cash flow or reported results.